Welcome to the UPF Digital Repository

Cannabinoids receptor type 2, CB2, expression correlates with human colon cancer progression and predicts patient survival

Show simple item record

dc.contributor.author Martínez-Martínez, Esther
dc.contributor.author Gómez, Irene
dc.contributor.author Martín, Paloma
dc.contributor.author Sánchez, Antonio J.
dc.contributor.author Román, Laura
dc.contributor.author Tejerina, Eva
dc.contributor.author Bonilla, Félix
dc.contributor.author García Merino, Antonio
dc.contributor.author García de Herreros, Antonio
dc.contributor.author Provencio, Mariano
dc.contributor.author García, Jose M.
dc.date.accessioned 2015-06-08T07:09:37Z
dc.date.available 2015-06-08T07:09:37Z
dc.date.issued 2015
dc.identifier.citation Martínez-Martínez E, Gómez I, Martín P, Sánchez A, Román L, Tejerina E. et al. Cannabinoids receptor type 2, CB2, expression correlates with human colon cancer progression and predicts patient survival. Oncoscience. 2015 Feb 9;2(2):131-41. DOI: 10.18632/oncoscience.119
dc.identifier.issn 2331-4737
dc.identifier.uri http://hdl.handle.net/10230/23750
dc.description.abstract Many studies have demonstrated that the endocannabinoid system (ECS) is altered in different tumor types, including colon cancer. However, little is known about the role of the ECS in tumor progression. Here we report the correlation between CB 2 expression and pathological data in a series of 175 colorectal cancer patients, as well as the response of the HT29 colon cancer-derived cell line upon CB 2 activation. CB 2 mRNA was detected in 28.6% of samples tested. It was more frequent in N+ patients and predicts disease free survival and overall survival in colon cancer. In positive samples, CB 2 was expressed with great intensity in tumor epithelial cells and correlated with tumor growth. Treatment of HT29 with CB 2 agonist revealed membrane loss of E-cadherin and SNAIL1 overexpression. A direct correlation between CB 2 and SNAIL1 expression was also found in human tumors. CB 2 receptor expression is a poor prognostic marker for colon cancer and the activation of this receptor, with non-apoptotic doses of agonists, could be collaborating with disease progression. These results raise the question whether the activation of CB 2 should be considered as anti-tumoral therapy.
dc.description.sponsorship This study was supported by AECC; ISCIIIPI10/00879 (Plan Nacional de I+D+I 2008-2011, FEDER funds co-financed), and ISCIII-RETIC RD12/0036/0041/n(Plan Estatal de I+D+I 2013-2016, FEDER funds cofinanced). JMG and EMM are supported by ISCIII, CP08/00217 and FI11/00696 respectively, (Plan Nacional/nde I+D+I 2008-2011, FEDER funds co-financed).
dc.format.mimetype application/pdf
dc.language.iso cat
dc.publisher Impact Journals
dc.relation.ispartof Oncoscience. 2015 Feb 9;2(2):131-41
dc.rights This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
dc.title Cannabinoids receptor type 2, CB2, expression correlates with human colon cancer progression and predicts patient survival
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.18632/oncoscience.119
dc.subject.keyword Colorectal cancer
dc.subject.keyword Prognosis marker
dc.subject.keyword CB2
dc.subject.keyword Disease free survival
dc.subject.keyword Overall survival
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion


This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


In collaboration with Compliant to Partaking